Evidence map›Paper›PMID 34790419›Full record

ArticleCase reports in pathology2021

Embryonal Rhabdomyosarcoma with Posttherapy Cytodifferentiation and Aggressive Clinical Course.

Maniraj Jeyaraju, Regina Ann Macatangay, Ashley Taylor-King Munchel, Teresa Anne York, Elizabeth A Montgomery, Michael E Kallen

Abstract readCase Reports
In one paragraph

Article in Case reports in pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maniraj JeyarajuUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Regina Ann MacatangayDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-3868-3287
Ashley Taylor-King MunchelDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
Teresa Anne YorkDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
Elizabeth A MontgomeryDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Michael E KallenDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-0470-7922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhabdomyosarcoma is the most common soft tissue sarcoma in children and adolescents. Embryonal rhabdomyosarcoma (ERMS), its most common subtype, is a malignant soft tissue tumor with morphologic and immunophenotypic features of embryonic skeletal muscle. The histologic findings in ERMS typically include a range of differentiation in rhabdomyoblasts from primitive to terminally differentiated forms, and the latter become more prominent after chemotherapy-induced cytodifferentiation. Several reports have shown therapy-related cytodifferentiation to portend a good prognosis in ERMS. We discuss the case of a pediatric patient who presented with ERMS of the orbit. Although her tumor showed extensive posttreatment cytodifferentiation and several other good prognostic clinicopathologic factors, it pursued an aggressive course, resulting in early metastasis and death. This case represents an unusual course and may be instructive as to the clinicopathologic features impacting prognostication, and ultimately the biology, of this aggressive family of tumors.

Identifiers

PMID34790419
PMCPMC8592761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.